multisectoral and shared value partnerships The sustained commitment and engagement of all UICC partners in 2021 allowed UICC to pursue its important agenda despite the pandemic. UICC has continued to drive impactful activities and programmes to empower and connect the cancer community, promoted greater equity and ensured that cancer remains a priority on the global health and development agenda. During the year, UICC further diversified its partnership base by welcoming new partners such as Revolution Watch, Becton, Dickinson and Company, GE Healthcare and BeiGene. UICC was also able to deepen the engagement with existing partners through World Cancer Day, the World Cancer Leaders’ Summit and the capacity building activities. For example, AstraZeneca organised a World Cancer Day Employee Donation Programme and Bristol Myers Squibb once again renewed its commitment to UICC and its members in Europe through the Country 2 Country Ride 4 Cancer. Both initiatives engaged the company’s staff and benefitted the cancer community. Thanks to the robust partnership with the American Society for Clinical Pathology (ASCP) and the engagement and support of UICC partners such as the National Cancer Institute in the US (NCI USA), the Canadian Partnership Against Cancer (CPAC), the French National Cancer Institute (INCa), Novartis, MSD, Daiichi Sankyo and others, UICC was able to drive impactful discussions around the nexus between innovation and equity during the World Cancer Leaders’ Summit.
2021 UICC Annual Report
Catalysing cancer control through
Together with longstanding partners like Sanofi, the Dutch Cancer Society (KWF), Cancer Research UK (CRUK), Roche and Pfizer, UICC moved the needle on specific areas of work such as leadership, cancer and ageing, tobacco control, women’s cancers and patient engagement, enabling the cancer community to be more effective and impactful. UICC is grateful that so many organisations wish to work with its members to extend the impact and reach of its work around the world and recognises the critical role that partners play in supporting UICC’s mission and expanding UICC’s scope and impact.
“Drug-resistant infections impact the care and treatment of millions of patients every year. And unfortunately, cancer patients are not only impacted but can be most affected by these infections. By partnering with UICC to raise awareness and to create impactful programmes, we have informed and educated advocates to drive innovation and policy to slow the impact of drug-resistant infections. Our future depends on what we do today.” Becton, Dickinson, and Co.
9
